Ampio Announces Voluntary Delisting and SEC Deregistration

Rhea-AI Summary

Ampio Pharmaceuticals, Inc. (AMPE) has decided to voluntarily delist its common stock from NYSE American and deregister its stock to terminate reporting obligations under the Exchange Act. The company notified NYSE American of this decision and plans to file a Form 25 with the SEC for delisting and deregistration.

Financial Analyst

The decision by Ampio Pharmaceuticals to delist from the NYSE American and deregister its common stock is a significant strategic move. This action typically suggests a desire to reduce regulatory burdens and costs associated with public reporting. It may also indicate that the company is seeking greater flexibility to operate without the scrutiny of public investors and analysts. For current shareholders, this could mean less liquidity and transparency, as the stock will no longer trade on a major exchange. However, the cost savings from reduced compliance requirements could potentially be redirected towards product development or operational efficiencies.

From a financial perspective, the impact on the stock's valuation could be mixed. On one hand, reduced visibility in the market can lead to a decrease in investor interest and, consequently, a lower stock price. On the other hand, if the company is able to leverage the cost savings and increased operational flexibility effectively, it could lead to improved financial performance over the long term. Stakeholders should monitor the company's future financial disclosures, if any and strategic moves closely to understand the implications of this decision.

Market Research Analyst

Delisting is a relatively rare event and often reflects underlying challenges or strategic shifts within a company. In the pharmaceutical industry, where investor sentiment can be heavily influenced by regulatory news and clinical trial results, the decision to delist might raise concerns about Ampio Pharmaceuticals' current performance and future prospects. Market participants might speculate that the company is facing challenges that could be mitigated by operating outside the public eye.

Additionally, the move to delist can affect the broader perception of the pharmaceutical sector, particularly among smaller cap companies. Investors might become more cautious about investing in similar companies due to perceived increased risks. This could result in a reevaluation of risk premiums for the sector. For potential institutional investors, the delisting could signal a red flag, prompting a more thorough due diligence process before any investment decision.

Legal Expert

The legal implications of Ampio Pharmaceuticals' decision to delist and deregister its common stock are considerable. The company will no longer be bound by the stringent reporting requirements of the Exchange Act, which could lead to a reduction in administrative overhead. However, this also means that the company will be subject to less regulatory oversight, which might concern investors about the company's governance and transparency.

It is also important to understand that the deregistration process involves legal complexities that must be handled meticulously to comply with SEC regulations. The company's intention to file a Form 25 with the SEC is the first step in this process. Shareholders and potential investors should be aware that once the company deregisters, they will likely have access to significantly less information about the company's financial health and operations, which could impact their ability to make informed investment decisions.

ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").

The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with the Securities and Exchange Commission ("SEC") to effect the delisting and deregistration of its common stock on or about April 4, 2024 and the delisting is expected to become effective on or about April 14, 2024.

Following the delisting of the Company's common stock from the NYSE American, the Company intends to file a Form 15 with the SEC on or about April 15, 2024 to suspend its reporting obligations under the Act. As a result of the filing of the Form 15, the Company's obligation to file certain Exchange Act reports and forms with the SEC, including Forms 10-K, 10-Q, and 8-K, will cease. Other SEC filing requirements will terminate upon the effectiveness of the deregistration. The Company expects that the deregistration of its common stock will become effective 90 days after the filing of the Form 15 with the SEC. The documents filed with the SEC will be available on the Company's website below.

The Board made the decision to pursue delisting and deregistration of its common stock following its review and careful consideration of a number of factors, including, but not limited to, the Company's current and likely future non-compliance with the continued listing requirements of the NYSE American that would inevitably result in delisting of the Company's common stock by the NYSE American and the required personnel resources and the high costs relating to Exchange Act and NYSE American disclosure and reporting requirements and related regulatory burdens, which have resulted and would continue to result in significant operating expense.  In light of these factors, the Board has determined that it is in the Company's best interests that the Company take steps designed to ensure sufficient cash to adequately fund an orderly wind down of the Company's operations and to maximize the Company's cash position.

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) had previously focused on the development of a potential treatment for osteoarthritis as part of its OA-201 program.  The OA-201 development program is exploring Ampio's unique and proprietary small molecule formulation as a potential treatment of osteoarthritis of the knee ("OAK") and other joints. As we announced in February 2024, the pain reduction benefit was not observed in the data from a set of non-clinical studies of OA-201, resulting in the termination of the OA-201 program at that time.

Caution Regarding Forward-Looking Statements

All statements other than statements of historical facts contained in this press release, including statements regarding future expectations, plans and prospects for the Company, including but not limited to statements about the expected timing of the delisting from the NYSE American and deregistration of the Company's common stock, the Company's ability to preserve cash in order to adequately fund an orderly wind down of the Company's operations, and the Company's actions to maximize the Company's cash position, are forward-looking statements. Words such as "may", "will", "should", "forecast", "could", "expect", "suggest", "believe", "estimate", "continue", "anticipate", "intend", "ongoing", "opportunity", "potential", "predicts", "seek", "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology, typically identify forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties including: (i) the ability to retain key personnel in order to pursue the wind down of the Company's operations, cash conservation plan, and resolution of the Company's pending legal proceedings; (ii) our available alternatives are limited and there is no assurance that any alternative will result in any distribution to or cash return to our stockholders; (iii) we plan to initiate steps to exit from certain reporting requirements under the Exchange Act, which will substantially reduce publicly available information about us; (iv) currently pending legal proceedings and any future legal proceedings may adversely affect our cash position and limit our pursuit of strategic options; (v) the settlement in principle of certain legal actions is subject to a number of conditions and risks; (vi) with the Board approval to delist our stock, we expect a negative impact on the price of our stock and the ability to sell our common stock in the public market; and (vii) other important factors that are described in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent periodic reports filed with the SEC.

We undertake no obligation to update or revise publicly any forward-looking statements to reflect events or circumstances after the date of such statements for any reason, except as otherwise required by law.

For more information, contact:

Ampio Pharmaceuticals, Inc.
Michael A. Martino
Chief Executive Officer
mmartino@ampiopharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-announces-voluntary-delisting-and-sec-deregistration-302098667.html

SOURCE Ampio Pharmaceuticals, Inc.

Why is Ampio Pharmaceuticals delisting its common stock from NYSE American?

Ampio Pharmaceuticals is delisting its common stock from NYSE American to terminate and suspend its reporting obligations under the Exchange Act.

What is the reason for Ampio Pharmaceuticals deregistering its common stock?

Ampio Pharmaceuticals is deregistering its common stock to terminate and suspend its reporting obligations under the Exchange Act.

What action is Ampio Pharmaceuticals taking regarding its common stock on NYSE American?

Ampio Pharmaceuticals is voluntarily delisting its shares of common stock from NYSE American.

What form will Ampio Pharmaceuticals file with the SEC for delisting and deregistration?

Ampio Pharmaceuticals intends to file a Form 25 with the SEC for the delisting and deregistration of its common stock.